<DOC>
	<DOCNO>NCT02976246</DOCNO>
	<brief_summary>Cardiovascular disease ( CVD ) frequent cause death patient ( ptt . ) chronic kidney disease ( CKD ) . Compared general population death due CVD 10-20 time higher CKD ptt . treat hemodialysis . Vascular calcification hence arterial stiffness great importance high incidence CVD . CKD ptt . dialysis treatment also 3 time high risk bone fracture . Both vertebral fracture low energy associate high mortality . Matrix Gla Protein ( MGP ) important inhibitor vascular calcification Osteocalcin ( OC ) important regulator bone metabolism . The function MGP OC depend vitamin K. Vitamin K supply food . The content low food recommend CKD ptt . reflect low concentration vitamin K blood sample . A correlation vitamin K level , incidence vascular calcification bone density proven ; yet trial elucidate clinical effect vitamin K vascular calcification bone strength . The investigator conduct randomize placebo control trial examine clinical effect vitamin K2 vascular calcification bone mineralization order prevent treat CVD bone disease CKD ptt . Primary study endpoint : 1 . Changes arterial stiffness assess pulse wave examination 2 . Changes bone mineral density ( BMD ) distal radius assess DXA-scans . Secondary study endpoint : Changes coronary artery valvular calcification assess heart-CT-scans , blood pressure , body composition , total regional BMD , lateral column/aortic calcification score well panel correlate blood test .</brief_summary>
	<brief_title>Effect Vitamin K2 ( MK7 ) Cardiovascular Bone Disease Dialysis Patients</brief_title>
	<detailed_description>BACKGROUND Vascular calcification significant problem among patient ( ptt . ) chronic kidney disease ( CKD ) prevalence aortic calcification twice high general population e.g . Cardiovascular disease ( CVD ) frequent cause death ptt . CKD . Death due CVD 10-20 time higher CKD ptt . treat hemodialysis compare background population . Whereas atherosclerosis dominate cause CVD general population CKD ptt . tend develop medial calcification hence arterial stiffness think great importance high incidence CVD . CKD ptt . dialysis treatment also 3 time high risk bone fracture compare general population . Both vertebral fracture low energy associate high mortality CKD ptt . The genesis arteriosclerosis still unresolved seem multifactorial . The impaired kidney function treatment far seem importance . The vitamin K-dependent Gla proteins ; Matrix Gla Protein ( MGP ) Osteocalcin ( OC ) describe potent inhibitor vascular calcification osteoporosis . Until recently CKD ptt . treat vitamin K antagonists add focus vitamin K progressive , vascular calcification- bone demineralization process . Vitamin K supply food . It consist several subtypes , e.g . vitamin K1 transform K2 digestion . The recommended diet CKD ptt . low vitamin K reflect low concentration vitamin K blood sample CKD ptt . hemodialysis . A supplement vitamin K1 K2 make activation possible MGP OC increase concentration vitamin K2 . A correlation vitamin K level incidence vascular calcification dialysis ptt . proven ; yet trial elucidate clinical effect vitamin K vascular calcification CKD ptt . There trial elucidate effect vitamin K bone strength number fracture dialysis ptt , although relation vitamin K bone mineral density dialysis ptt . show significant increase age relate bone strength find study introduce daily supplement vitamin K. OBJECTIVE AND HYPOYHESIS To examine clinical effect vitamin K2 ( MK7 ) arterial stiffness assess pulse wave examination bone mineral density assess DXA-scans group dialysis ptt . order able prevent treat cardiovascular bone disease CKD ptt . future . The hypothesis daily supplement vitamin K2 ( MK7 ) reduce calcification process large artery , coronary artery -valves hence reduce risk CVD well increase bone mineral density hence frequency bone fracture . DESIGN RenaKvit investigator initiate , prospective , randomize , double-blinded , placebo control intervention trial perform nationally , multicenter trial run 2 year . Data compile 1 2 year . The trial divide two sub-studies ; RenaKvit-kar ( vessel ) RenaKvit-knogle ( bone ) , effect vitamin K2 ( MK7 ) large artery , coronary arteries- valve effect bone regard bone mineral density frequency fracture respectively examine . PATIENTS AND RECRUITMENT Ptt . equally divided randomization hence daily give tablet either vitamin K2 ( MK7 ) placebo . According criterion inclusion ptt . either join RenaKvit-vessel bone group . If criterion fulfil ptt . join vessel bone group . Determined calculation statistical power , incl . level significance 5 % , standard deviation 0,95 strength 80 % , minimum 40 + 140 ptt . include , thus take potentially drop-outs account . Both ptt . hemo- peritoneal dialysis treatment include . Ptt . recruit dialysis department Roskilde , Nykoebing falster , Holbaek Slagelse Hospitals . There fee participate ptt . MEDICINE Patients give either vitamin K 360 microgram placebo daily period 2 x 12 month . Both type tablet similar look content , besides vitamin K2 . METHODS - Pulse Wave examination : Includes pulse wave analysis pulse wave velocity measurement . Done use SphygmoCor©-pulse wave apparatus . Pulse wave examination use measure arterial stiffness perform standardized method . - 24-hour blood pressure blood pressure measurement : Done current Danish guideline ( 17 ) . - Coronary artery -valve calcification : Assessed CT-scans heart use Agatston Score . - Bone Mineral Density : Assessed DEXA-scans . - Lateral lumbal x- ray aortic calcification score : A semi-quantitative scoring system use describe plaque front back aorta level level lumbar vertebra . The method find predictive vascular morbidity mortality . - Measuring predictors/establishing biobank : Partly `` routine test '' dialysis partly special kit develop Vejle Hospital . STATISTICS Both group descriptive statistic perform well presentation total population , stratify gender , age weight . Normal-distributed data express mean value +/- standard deviation ( SD ) , distribute data also express median value ( interquartile range ; interquartile range , IQR ) . Categorical value express number percentage . Normal-distributed variable compare Student 's t-test . Where found appropriate , logarithmic transformation shall perform . Non-normally distributed variable compare Mann Whitney U test . Categorical value compare Chi Square test . Changes two group time analyze paired analysis , two group compare non-paired analysis . Forward stepwise multivariate logistic regression analysis carry correct significant confounders primary secondary endpoint . Analysis Cox proportional hazard perform time first clinical event . P≤0.05 consider statistically significant . All result - negative positive - expect published peer-review magazine .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Vitamin K 2</mesh_term>
	<mesh_term>Vitamin MK 7</mesh_term>
	<criteria>Age ≥ 18 year old Life expectancy &gt; 2 year Written consent follow oral information Permanent treatment dialysis ≥ 3 month either peritoneal hemodialysis Treatment vitamin K vitamin Kantagonist begin trial 1 month within . Chronic GImalabsorption lead slow bowel transit ( e.g . Celiac disease , Short bowel syndrome ) . Ongoing malignancy ( ongoing treatment/clinical control visit diagnose less 5 year ago ) , excl . NonMelanomaSkinCancer ( NMSC ) . Abuse alcohol euphoric drug . Women pregnant breastfeed woman childbearing age without contraception . Total/subtotal parathyroidectomy Treatment recombine PTH . Treatment bisphosphonates antiosteoporotic drug ( Selective Estrogen Reuptake Modulators ( SERM ) , strontium , renalat , denosumab ) . Only RenaKvitkar ( vessel ) : Atrial fibrillation/other arrhythmia significance Aortic stenosis significance Agatston score &lt; 100 heartCTscan Bilateral upper arm fistula Amputation metatarsal level Criteria withdrawal : Kidney transplantation Starting treatment vitamin Kantagonists Wish draw participant Unacceptable side effect ingestion vitamin K placebo Reasonable suspicion lack compliance regard medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>